| Improved survival with vemurafenib in melanoma with BRAF V600E mutation PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ... New England Journal of Medicine 364 (26), 2507-2516, 2011 | 9057 | 2011 |
| Combined nivolumab and ipilimumab or monotherapy in untreated melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ... New England journal of medicine 373 (1), 23-34, 2015 | 7869 | 2015 |
| Nivolumab in previously untreated melanoma without BRAF mutation C Robert, GV Long, B Brady, C Dutriaux, M Maio, L Mortier, JC Hassel, ... New England journal of medicine 372 (4), 320-330, 2015 | 6008 | 2015 |
| Overall survival with combined nivolumab and ipilimumab in advanced melanoma JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ... New England Journal of Medicine 377 (14), 1345-1356, 2017 | 3529 | 2017 |
| Five-year survival with combined nivolumab and ipilimumab in advanced melanoma J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ... New England journal of medicine 381 (16), 1535-1546, 2019 | 3009 | 2019 |
| Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial JS Weber, SP D'Angelo, D Minor, FS Hodi, R Gutzmer, B Neyns, ... The lancet oncology 16 (4), 375-384, 2015 | 2951 | 2015 |
| Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma J Larkin, PA Ascierto, B Dréno, V Atkinson, G Liszkay, M Maio, M Mandalà, ... New England Journal of Medicine 371 (20), 1867-1876, 2014 | 2367 | 2014 |
| Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma J Weber, M Mandala, M Del Vecchio, HJ Gogas, AM Arance, CL Cowey, ... New England Journal of Medicine 377 (19), 1824-1835, 2017 | 2189 | 2017 |
| Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study A Marabelle, DT Le, PA Ascierto, AM Di Giacomo, A De Jesus-Acosta, ... Journal of Clinical Oncology 38 (1), 1, 2020 | 2182 | 2020 |
| International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study F Pagès, B Mlecnik, F Marliot, G Bindea, FS Ou, C Bifulco, A Lugli, ... The Lancet 391 (10135), 2128-2139, 2018 | 1800 | 2018 |
| Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ... The lancet oncology 16 (8), 908-918, 2015 | 1754 | 2015 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma AMM Eggermont, CU Blank, M Mandala, GV Long, V Atkinson, S Dalle, ... New England Journal of Medicine 378 (19), 1789-1801, 2018 | 1742 | 2018 |
| Towards the introduction of the ‘Immunoscore’in the classification of malignant tumours J Galon, B Mlecnik, G Bindea, HK Angell, A Berger, C Lagorce, A Lugli, ... The Journal of pathology 232 (2), 199-209, 2014 | 1473 | 2014 |
| Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy AMM Eggermont, V Chiarion-Sileni, JJ Grob, R Dummer, JD Wolchok, ... New England Journal of Medicine 375 (19), 1845-1855, 2016 | 1423 | 2016 |
| Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial AMM Eggermont, V Chiarion-Sileni, JJ Grob, R Dummer, JD Wolchok, ... The lancet oncology 16 (5), 522-530, 2015 | 1338 | 2015 |
| Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial SJ Antonia, JA López-Martin, J Bendell, PA Ott, M Taylor, JP Eder, ... The Lancet Oncology 17 (7), 883-895, 2016 | 1290 | 2016 |
| Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study GA McArthur, PB Chapman, C Robert, J Larkin, JB Haanen, R Dummer, ... The lancet oncology 15 (3), 323-332, 2014 | 1196 | 2014 |
| Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial PA Ascierto, GA McArthur, B Dréno, V Atkinson, G Liszkay, ... The lancet oncology 17 (9), 1248-1260, 2016 | 1094 | 2016 |
| Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial GV Long, U Trefzer, MA Davies, RF Kefford, PA Ascierto, PB Chapman, ... The lancet oncology 13 (11), 1087-1095, 2012 | 1017 | 2012 |
| Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial R Dummer, PA Ascierto, HJ Gogas, A Arance, M Mandala, G Liszkay, ... The Lancet Oncology 19 (5), 603-615, 2018 | 976 | 2018 |
Georgina V LongMelanoma Institute Australia, The University of Sydney and Royal North Shore Hospital確認したメール アドレス: sydney.edu.au
